D. E. Shaw & Co., Inc. Kymera Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 295,572 shares of KYMR stock, worth $12.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
295,572
Previous 67,762
336.19%
Holding current value
$12.8 Million
Previous $2.72 Million
223.86%
% of portfolio
0.01%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding KYMR
# of Institutions
160Shares Held
63.1MCall Options Held
22.6KPut Options Held
14.4K-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$277 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$260 Million2.38% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.35MShares$232 Million21.28% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$224 Million4.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$209 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.37B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...